News &

Home 9 Dermapharm Corporate News 9 | Dermapharm to expand capacities at its main production site in Brehna

| Dermapharm to expand capacities at its main production site in Brehna


Corporate news

to the archive

Dermapharm to expand capacities at its main production site in Brehna

  • Topping out ceremony for new logistics center in Brehna near Leipzig
  • Expansion of the production site by 12,400 m²
  • Total investments for new construction of around EUR 11 million
  • Commitment to Germany as a business location and creation of the logistical prerequisites for the continued growth of the Dermapharm Group

Grünwald, April 26, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, celebrated the topping-out ceremony for the new logistics center of its subsidiary mibe GmbH Arzneimittel in Brehna near Leipzig on April 25, 2019. The new building expands the existing production site by around 12,400 m² to a total of over 50,000 m² and thus creates the logistical prerequisites for the continued growth of the Dermapharm Group.

The individual divisions of the company, from in-house product development and pharmaceutical production to dispatch and sales in the spatial arrangement, are efficiently interlinked at the Brehna production site. The new building will now make an important contribution to this and will also create the conditions for further expanding production. In Brehna, a wide variety of pharmaceutical dosage forms, including sterile pharmaceuticals such as ampoules and freeze-drying products, tablets, coated tablets, capsules, ointments, solutions, drops and sprays, can be manufactured under one roof. This technological diversity makes the Brehna production site unique. Well-known branded pharmaceuticals manufactured in Brehna include Dekristol®, Solacutan® and Prednisolut®, for example, but also many products known especially in Central Germany such as Panthenol eye ointment, Simagel® and Summavit®.

Mibe GmbH Arzneimittel is Dermapharm’s largest production site. Around 90% of the extensive product portfolio “Made in Germany” is manufactured here and at the other German sites of the group.

“We deliberately chose Brehna for the expansion of our production and logistics capacities. We are continuing to invest in the region in which we have been deeply rooted with our subsidiary mibe for 16 years now. We are thus also committed to Germany as a production location and guarantee our customers the highest manufacturing quality,” said Dr. Hans-Georg Feldmeier, CEO of Dermapharm, in commenting on the capacity expansion.

The ground-breaking ceremony took place in September 2018. The completion of the logistics center is scheduled for September 2019. The investments for the new building total around EUR 11 million. The project will be supported with EUR 1.65 million in subsidies from the state of Saxony-Anhalt. More than 570 employees are currently employed in Brehna, including around 20 trainees. The new dispatch hall offers potential for further jobs and apprenticeships in the area of logistics.

Images of the construction process:

Investor Relations

Britta Hamberger
Phone: +49 (0)89 – 64186-233
Fax: +49 (0)89 – 64186-165

cometis AG
Claudius Krause
Phone: +49 (0)611 – 205855-28
Fax: +49 (0)611 – 205855-66

Company profile

Dermapharm – Pharmaceutical Excellence “Made in Germany”

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2018. In the “Herbal Extracts” segment, Dermapharm has access to the growth market for plant pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturer of plant extracts and plant-based active ingredients.

With a consistent development strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.